Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

MRKMerck Sharp & Dohme LLCSigning up patients

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Colon Adenocarcinoma · Rectal Adenocarcinoma

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 5 insiders sold shares within a month

    Since Aug 13, 2026 · was worth 5, fading over time

    +1.9
Worry score2

Score over time

Stage
Phase 3
Patients
477 (planned)
Started
Jul 16, 2025
Main results expected
Mar 28, 2029
Fully finished
Oct 27, 2030
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Number of Participants Experiencing Dose-Limiting Toxicity (DLT)

    Measured over: Up to approximately 28 days

  • Part 1: Number of Participants Who Experience an Adverse Event (AE)

    Measured over: Up to approximately 44 months

  • Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE

    Measured over: Up to approximately 44 months

  • Progression Free Survival (PFS)

    Measured over: Up to approximately 44 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT06997497 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06997497) ↗